Products from TransMed7's technology pipeline currently under development are designed to address critical healthcare needs in medical fields such as breast health; soft tissue surgery, including small or fragile tissues and challenging surgical spaces, with endoscopy, laparoscopy, and robotics applications; bone marrow biopsy and harvest; interventional cardiology; and minimally invasive peripheral vascular procedures.
"This new strategic partnership with Peridot enables TransMed7 to launch new products such as our Concorde and Martinet technologies directly into the market immediately following FDA clearance. Peridot was our contract manufacturer for our SpeedBird platform needle sets, and we are excited to be expanding our relationship with Peridot for timed product commercial release in significant quantities for strategic market penetration," said Eugene H. Vetter, TransMed7's Co-Founder and CEO.
TransMed7 is focused on the development of minimally invasive medical devices. With particular expertise in both oncologic and cardiovascular disease, the company and its team of clinicians, scientists, and engineers have developed a portfolio of next-generation platform devices.
Peridot offers complete end-to-end precision manufacturing and clean room assembly services to a wide range of industries. With over twenty years' experience with device fabrication and precision miniature and micro-miniature component assembly, the company can design, prototype, test and deliver products with precision and versatility.
Clene Inc closes registered direct offering of common stock to existing shareholders
Insmed's ARIKAYCE sNDA granted priority review by FDA
Precigen announces FDA platform technology designation for AdenoVerse
Enhertu recommended for EU approval in early HER2-positive breast cancer
PureTech receives FDA Fast Track designation for LYT-200 in HR-MDS
MaaT Pharma outlines potential Phase 3 development plan for MaaT013 after CHMP negative opinion
Bayer's Kerendia wins FDA approval for chronic kidney disease associated with type 1 diabetes
Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase
Medtronic receives FDA clearance for LigaSure RAS Maryland instrument on Hugo system
VaxThera partners with Codagenix for next generation yellow fever vaccine advancement
MaaT Pharma receives negative CHMP trend vote for MaaT013
FDA approves Scholar Rock's ISEMBYLD to treat spinal muscular atrophy
FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis